<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480649</url>
  </required_header>
  <id_info>
    <org_study_id>100614</org_study_id>
    <nct_id>NCT00480649</nct_id>
  </id_info>
  <brief_title>Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)</brief_title>
  <official_title>SUccessful Control and Clinical Effectiveness of SERETIDE Study in aSthma, a Randomised Controlled Study to Investigate the Clinical Effectiveness and Health Outcome of SERETIDE in Patients With Moderate and Severe Persistent Asthma in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study objective is to demonstrate the clinical effectiveness of SERETIDE therapy
      compared to the current care in management of moderate to severe persistent asthma patients
      in Korea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint for this trial is mean morning PEFR LOCF at 52 weeks as collected in diary cards over the last 2 weeks preceding the 52 weeks visit.</measure>
    <time_frame>52 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary measures of efficacy consist of clinical efficacy and health outcome measurements.</measure>
    <time_frame>52 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">424</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sal/FP 50/250mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SERETIDE 50/250</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sal/FP 50/500mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SERETIDE 50/500</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol/ fluticasone propionate</intervention_name>
    <description>2 active arms (parellel group)</description>
    <arm_group_label>Sal/FP 50/250mcg</arm_group_label>
    <arm_group_label>Sal/FP 50/500mcg</arm_group_label>
    <other_name>SERETIDE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female subjects aged 18 years and over who are willing to give a written
             consent to participate in the study.

          -  Subjects with a documented clinical history of reversible airways obstruction (history
             taking is acceptable) for at least 12 months and, in the opinion of the investigator,
             is able to comply with therapy and to complete the Daily Record Cards (DRCs)
             correctly.

          -  Subjects able to demonstrate the ability to effectively (physically and/or mentally)
             use a DISKUS (a dummy DISKUS provided for test).

          -  A female is eligible to enter and participate in this study

          -  Subjects with access to telephone (mobile or landline at home)

        Exclusion criteria:

          -  Previous use of ICS /LABA combination inhaler (SYMBICORT (Astrazeneca) or SERETIDE) 12
             weeks prior to Visit 1.

          -  Subjects with known or suspected hypersensitivity to inhaled steroids or
             Beta2-agonists.

          -  Subjects who have had other changes in their regular asthma medication within 2 weeks
             of Visit 1.

          -  Subjects who have had a lower respiratory tract infection within 4 weeks of Visit 1.

          -  Subjects who have a smoking history of 10 pack years (e.g. 10 cigarettes/day for 20
             years or 20 cigarettes/day for 10 years or 40 cigarettes/day for 5 years) or more at
             the time of Visit 1 (Current smoker can be included even if his/her smoking history is
             less than 10 pack years at the time of Visit 1).

          -  Subjects who suffer from serious, uncontrolled diseases (including serious
             psychological disorders) likely to interfere with the study.

          -  Subjects who are on immunotherapy

          -  Subjects who have taken any investigational drugs within 4 weeks of Visit 1.

          -  Subjects who have, in the opinion of the investigator, evidence of alcohol or drug
             abuse.

          -  Females who are pregnant, lactating or are of child bearing potential and are likely
             to become pregnant. Females of childbearing age may be included if, in the opinion of
             the investigator, they are exerting adequate contraceptive precautions.

          -  Subjects who have previously been enrolled into this study

          -  Patients on regular oral or parenteral steroid therapy in the last 4 weeks or more
             than 3 courses of steroid in the last 6 months

          -  Subjects who have FEV1 or PEFR of less than 50% predictive value.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anyang-Si</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Busan-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Junjoo-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyungki-Do Anyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyungki-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>140-743</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>서울시</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>전주시</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Jung KS, Uh ST, Lee YC, Shim JJ, Park SK, Williams AE, Chan R. Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. Curr Med Res Opin. 2008 Dec;24(12):3571-82. doi: 10.1185/03007990802588737 .</citation>
    <PMID>19032138</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2007</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SERETIDE</keyword>
  <keyword>asthma</keyword>
  <keyword>Korean</keyword>
  <keyword>ACT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

